Synthetic tetrapeptide bioregulator · Fact sheet
Cortagen
Also known as Ala-Glu-Asp-Pro · AEDP peptide
Cortagen is a synthetic tetrapeptide studied for nerve-related and gene-expression effects. Rat nerve-repair findings and claims in paper introductions do not establish a reliable human recovery treatment.
What is Cortagen?
Cortagen is Ala-Glu-Asp-Pro in the cited research. Cortexin is a different brain-derived peptide preparation.
A shared research lineage does not make the defined tetrapeptide equivalent to the tissue extract.
Benefits & claims
Interest centers on brain function and sleep, tissue repair. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- A rat sciatic-nerve experiment reported changes in nerve growth and conduction measures.
- The mouse microarray study measured transcription, not recovery of human nerve function.
- General statements about prior human effects without adequate direct methods are insufficient to establish efficacy.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Cortagen. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Cortagen is Ala-Glu-Asp-Pro in the cited research. Cortexin is a different brain-derived peptide preparation.
Formulation differences
- A shared research lineage does not make the defined tetrapeptide equivalent to the tissue extract.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Human neurologic, immune and repeated-exposure safety are insufficiently characterized.
- Expression of multiple genes does not establish a beneficial or selective organ effect.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe direct primary results cited include rat sciatic-nerve repair and mouse cardiac gene-expression experiments. Robust human functional efficacy is not established.
Studies
Rat sciatic-nerve transection and repair experiment.
Related injured-nerve function report with sparse indexed detail.
Mouse-heart transcriptome study; distinguishes Cortagen from Cortexin.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Cortagen has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
General statements about prior human effects without adequate direct methods are insufficient to establish efficacy.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedEffect of tetrapeptide cortagen on regeneration of sciatic nerve.
Rat sciatic-nerve transection and repair experiment.
- pubmedThe delayed effect of cortagen on the restoration of injured nerve function.
Related injured-nerve function report with sparse indexed detail.
- pubmedElucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray.
Mouse-heart transcriptome study; distinguishes Cortagen from Cortexin.